Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...

Arvinas (NASDAQ:ARVN) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Pfizer Inc. reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance. “Our overall solid first-quarter performance demonstrates our continued focus on ...